Different BCR–ABL–dependent mechanisms of imatinib resistance have been discovered, including amplification of the BCR-ABL oncogene, changes in BCR-ABL localization in CML cells, and mutations in the BCR-ABL oncogene. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.